About HLA class II histocompatibility antigen, DP alpha 1 chain
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1) is a protein
from Homo sapiens identified by UniProt accession
P20036, 260 residues long.
MolForge cross-references it against 0 known binders and
228 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DP alpha 1 chain |
|---|
| UniProt accession | P20036 |
|---|
| Gene | HLA-DPA1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 260 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (228)
Diseases linked to this target (Open Targets).
- systemic lupus erythematosus · score 0.29
- Graves disease · score 0.28
- hepatitis B virus infection · score 0.28
- chronic hepatitis B virus infection · score 0.25
- anti-neutrophil antibody associated vasculitis · score 0.24
- cervical carcinoma · score 0.22
- allergic disease · score 0.20
- asthma · score 0.19
- susceptibility to hepatitis B infection measurement · score 0.18
- childhood onset asthma · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P20036-F1 | alphafold | PREDICTED | 90.10 | — |
Amino-acid sequence (260 residues)
MRPEDRMFHI RAVILRALSL AFLLSLRGAG AIKADHVSTY AAFVQTHRPT GEFMFEFDED EMFYVDLDKK ETVWHLEEFG QAFSFEAQGG LANIAILNNN LNTLIQRSNH TQATNDPPEV TVFPKEPVEL GQPNTLICHI DKFFPPVLNV TWLCNGELVT EGVAESLFLP RTDYSFHKFH YLTFVPSAED FYDCRVEHWG LDQPLLKHWE AQEPIQMPET TETVLCALGL VLGLVGIIVG TVLIIKSLRS GHDPRAQGTL
Explore HLA class II histocompatibility antigen, DP alpha 1 chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets